Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Grauer & Weil (India) Limited is a specialty chemicals manufacturer serving industrial and pharmaceutical end-markets in India and export markets. The company operates manufacturing facilities producing intermediates, fine chemicals, and specialty formulations with established customer relationships in regulated markets. Stock performance reflects margin compression from input cost volatility and competitive pressures in commodity-grade chemical segments.
The company generates revenue through contract manufacturing and sale of specialty chemical products with pricing determined by raw material costs plus conversion margins. Competitive advantages include established regulatory approvals for pharmaceutical-grade products, technical expertise in complex synthesis, and long-term customer contracts that provide revenue visibility. Gross margins of 36.6% reflect value-added processing capabilities, though operating leverage is constrained by batch manufacturing processes and working capital intensity typical of chemical intermediates.
Raw material cost inflation particularly crude oil derivatives, benzene, toluene, and specialty solvents impacting gross margins
Pharmaceutical API demand from domestic formulation companies and export customers in regulated markets
Agrochemical industry capex cycles driving demand for intermediates during planting seasons
INR/USD exchange rate movements affecting export competitiveness and rupee-denominated earnings from dollar contracts
Capacity utilization rates at manufacturing facilities and new product commercialization timelines
Environmental regulations tightening in India requiring pollution control capex and potentially restricting operations of chemical manufacturing facilities in urban/semi-urban areas
Chinese competition in commodity chemical intermediates with cost advantages from scale and vertical integration, pressuring margins on non-differentiated products
Pharmaceutical industry consolidation reducing number of customers and increasing buyer negotiating power for contract manufacturing services
Domestic specialty chemical manufacturers expanding capacity in similar product categories, particularly larger players with better access to capital for backward integration
Loss of key customer contracts or product approvals in regulated export markets due to quality issues or competitive displacement
Inability to pass through raw material cost increases in fixed-price contracts leading to margin compression during commodity price spikes
Working capital intensity requiring significant cash tied up in inventory and receivables, limiting financial flexibility despite low debt levels
Capex requirements for facility upgrades, environmental compliance, and new product development competing with shareholder returns given 4.0% FCF yield
moderate - Revenue linked to industrial production through pharmaceutical manufacturing activity and agrochemical demand tied to agricultural output. Pharmaceutical intermediates provide defensive characteristics with steady prescription drug demand, while agrochemical exposure creates seasonality and sensitivity to rural income levels. Industrial chemical sales correlate with manufacturing PMI and capital goods production cycles in India.
Moderate sensitivity through working capital financing costs given high inventory requirements and 60-90 day receivables cycles typical in chemical distribution. Current ratio of 2.98 and minimal debt (0.01 D/E) insulate from rate volatility, but customer industries (pharma, agro) face financing pressures during rate hiking cycles that can delay orders. Rising rates in developed markets strengthen USD, benefiting export realizations but potentially reducing global chemical demand.
Minimal direct credit exposure given strong balance sheet and low leverage. Indirect exposure through customer credit quality as pharmaceutical and agrochemical buyers may face working capital constraints during tight credit conditions. Trade receivables management critical given 90-120 day payment terms common in Indian chemical industry.
value - Trading at 2.8x P/S and 13.9x EV/EBITDA with 16.1% ROE attracts value investors seeking exposure to India's specialty chemical sector at reasonable multiples. Recent 22.8% decline creates potential entry point for investors betting on margin recovery and export growth. 4.0% FCF yield and minimal leverage appeal to quality-focused value managers, though lack of dividend limits income investor interest.
high - Stock exhibits elevated volatility typical of mid-cap Indian specialty chemical companies with beta likely 1.2-1.5x. Recent 14.5% decline in three months reflects sector-wide derating and commodity cost pressures. Volatility driven by quarterly margin fluctuations, INR movements, and episodic large order announcements creating lumpy revenue patterns.